David Fenton

4.8k total citations
38 papers, 1.2k citations indexed

About

David Fenton is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, David Fenton has authored 38 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 6 papers in Epidemiology. Recurrent topics in David Fenton's work include Lung Cancer Treatments and Mutations (10 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Research Studies (4 papers). David Fenton is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Research Studies (4 papers). David Fenton collaborates with scholars based in Canada, United Kingdom and United States. David Fenton's co-authors include Frances A. Shepherd, Mauro Zukin, Lesley Seymour, Francis Laberge, Charles Butts, Jonathan Noble, Carolyn J. Peddle‐McIntyre, Quincy S. Chu, Michael Smylie and Kerry S. Courneya and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Journal of Urology.

In The Last Decade

David Fenton

36 papers receiving 1.1k citations

Peers

Countries citing papers authored by David Fenton

Since Specialization

Citations

This map shows the geographic impact of David Fenton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Fenton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Fenton more than expected).

Fields of papers citing papers by David Fenton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Fenton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Fenton. The network helps show where David Fenton may publish in the future.

Co-authorship network of co-authors of David Fenton

This figure shows the co-authorship network connecting the top 25 collaborators of David Fenton. A scholar is included among the top collaborators of David Fenton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Fenton. David Fenton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation 2025 ·European Journal of Cancer ·(unknown), (unknown), (unknown), (unknown), Gilbert Bigras, David Fenton, (unknown), Yan Yuan, Kurian Joseph	0
2	Impact of the 21-Gene Recurrence Score Assay on the Treatment of Estrogen Receptor-Positive, HER2-Negative, Breast Cancer Patients With 1-3 Positive Nodes: A Prospective Clinical Utility Study 2021 ·Clinical Breast Cancer ·Nathalie LeVasseur, (unknown), David Fenton, Simon W. Baxter, Angela Chan, (unknown), Xiaolan Feng, Caroline Lohrisch, Karen A. Gelmon, Tamara Shenkier, Stephen Chia	9
3	Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab 2021 ·Translational Lung Cancer Research ·Doran Ksienski, Elaine S. Wai, Deepu Alex, Nicole S. Croteau, (unknown), Angela Chan, (unknown), (unknown), (unknown), (unknown), David Fenton, (unknown), Mary Lesperance	34
4	Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab 2020 ·Journal of Geriatric Oncology ·Doran Ksienski, Elaine S. Wai, Nicole S. Croteau, (unknown), Angela Chan, (unknown), (unknown), David Fenton, (unknown), (unknown), Mary Lesperance	21
5	Treatment of Non-Small-Cell Lung Cancer after Progression on Nivolumab or Pembrolizumab 2020 ·Current Oncology ·(unknown), Mary Lesperance, Elaine S. Wai, Nicole S. Croteau, (unknown), (unknown), Edward G. Brooks, (unknown), David Fenton, (unknown), Doran Ksienski	6
6	Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice 2019 ·Lung Cancer ·Doran Ksienski, Elaine S. Wai, Nicole S. Croteau, (unknown), Angela Chan, (unknown), Edward G. Brooks, (unknown), David Fenton, (unknown), (unknown), Mary Lesperance	36
7	Resolution of Metastatic Colon Cancer upon Withdrawal of Anti-TNF Therapy for Crohn’s Disease 2018 ·Journal of Gastrointestinal Cancer ·(unknown), Howard Joe, David Fenton, James K. Kelly, Pauline T. Truong	1
8	Gastric Acid Suppression Is Associated With Decreased Erlotinib Efficacy in Non–Small-Cell Lung Cancer 2014 ·Clinical Lung Cancer ·Michael P. Chu, Sunita Ghosh, Carole Chambers, Naveen S. Basappa, Charles Butts, Quincy S. Chu, David Fenton, Anil A. Joy, Randeep Sangha, Michael Smylie, Michael B. Sawyer	80
9	Timeliness of cancer care from diagnosis to treatment: a comparison between patients with breast, colon, rectal or lung cancer 2013 ·International Journal for Quality in Health Care ·Xue Li, Andrew Scarfe, Karen King, David Fenton, Charles Butts, Marcy Winget	30
10	Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29 2013 ·European Journal of Cancer ·Scott A. Laurie, Benjamin Solomon, Lesley Seymour, Peter Ellis, Glenwood Goss, F. Shepherd, Michael Boyer, Andrew Arnold, Philip R. Clingan, Francis Laberge, David Fenton, Vera Hirsh, Mauro Zukin, Martin R. Stockler, (unknown), (unknown), (unknown), Keyue Ding, Penelope A. Bradbury	79
11	Outcome analysis of breast cancer patients who declined evidence-based treatment 2012 ·World Journal of Surgical Oncology ·Kurian Joseph, (unknown), (unknown), (unknown), David Fenton, Richard Berendt, Edward Yu, Patricia Tai	54
12	Utilization of oncology services and receipt of treatment: a comparison between patients with breast, colon, rectal, or lung cancer 2011 ·Annals of Oncology ·(unknown), Charles Butts, David Fenton, Karen King, Andrew Scarfe, Marcy Winget	12
13	Feasibility and preliminary efficacy of progressive resistance exercise training in lung cancer survivors 2011 ·Lung Cancer ·Carolyn J. Peddle‐McIntyre, Gordon J. Bell, David Fenton, Linda McCargar, Kerry S. Courneya	60
14	Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer 2011 ·Radiotherapy and Oncology ·Don Yee, Charles Butts, Tony Reiman, Anil A. Joy, Michael Smylie, David Fenton, Quincy S. Chu, John Hanson, Wilson Roa	67
15	Fallopian tube carcinoma presenting with an abnormal glandular smear 2010 ·Journal of Obstetrics and Gynaecology ·(unknown), David Fenton	2
16	Phase I dose escalation trial of hypofractionated limited-field external beam thoracic radiotherapy for limited-stage small cell carcinoma of the lung 2010 ·Radiotherapy and Oncology ·Don Yee, John Hanson, Charles Butts, Tony Reiman, Anil A. Joy, Michael Smylie, David Fenton, Quincy S. Chu, Wilson Roa	10
17	A Randomized Phase 2 Study of Erlotinib Alone and in Combination with Bortezomib in Previously Treated Advanced Non-small Cell Lung Cancer 2009 ·Journal of Thoracic Oncology ·Thomas J. Lynch, David Fenton, Vera Hirsh, David Bodkin, Edward L. Middleman, Alberto Chiappori, Balázs Halmos, Reyna Favis, Hua Liu, William L. Trepicchio, Omar Eton, Frances A. Shepherd	52
18	Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study 2009 ·Journal of Clinical Oncology ·Glenwood Goss, Andrew Arnold, Frances A. Shepherd, Mircea Dediu, Tudor–Eliade Ciuleanu, David Fenton, Mauro Zukin, David Walde, Francis Laberge, Mark Vincent, Peter Ellis, Scott A. Laurie, Keyue Ding, Eliot Frymire, Isabelle Gauthier, Natasha B. Leighl, Cheryl Ho, Jonathan Noble, Christopher W. Lee, Lesley Seymour	186
19	A case controlled study of the outcome of pregnancy following loop diathermy excision of the transformation zone 1994 ·Journal of Obstetrics and Gynaecology ·(unknown), (unknown), David Fenton	25
20	Ultrasonic tissue characterization of the placenta: Is it of clinical value? 1985 ·Journal of Clinical Ultrasound ·Diane Crawford, David Fenton, (unknown)	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact